A carregar...
Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis
Risankizumab, a fully human IgG monoclonal antibody inhibitor of IL-23, is a therapeutic agent currently in late stage development for use in the treatment of moderate-to-severe plaque psoriasis. It is a biologic agent similar to guselkumab and tildrakizumab which targets IL-23 specifically, and has...
Na minha lista:
| Publicado no: | Drug Des Devel Ther |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6237136/ https://ncbi.nlm.nih.gov/pubmed/30518998 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S167149 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|